Head-To-Head Analysis: BioAffinity Technologies (NASDAQ:BIAF) Versus Inotiv (NASDAQ:NOTV)
Head-To-Head Analysis: BioAffinity Technologies (NASDAQ:BIAF) Versus Inotiv (NASDAQ:NOTV)
bioAffinity Technologies (NASDAQ:BIAF – Get Rating) and Inotiv (NASDAQ:NOTV – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
生物親和科技(納斯達克：BIAF-GET評級)和艾諾維奇(納斯達克：NOT-GET評級)都是小盤股醫療公司，但哪種投資更好？我們將根據這兩家公司的收益、風險、估值、股息、分析師建議、機構所有權和盈利能力來比較它們的實力。
Insider and Institutional Ownership
內部人與機構持股
52.1% of Inotiv shares are owned by institutional investors. 9.8% of Inotiv shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
INotiv 52.1%的股份由機構投資者持有。伊諾維奇9.8%的股份由內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一家公司有望實現長期增長。
Profitability
盈利能力
This table compares bioAffinity Technologies and Inotiv's net margins, return on equity and return on assets.
此表比較了BioAffity Technologies和INotiv的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| bioAffinity Technologies | N/A | N/A | N/A |
| Inotiv | -19.54% | -4.23% | -2.25% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 生物親和技術 | 不適用 | 不適用 | 不適用 |
| 通知 | -19.54% | -4.23% | -2.25% |
Earnings and Valuation
收益和估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioAffinity Technologies | N/A | N/A | N/A | N/A | N/A |
| Inotiv | $89.61 million | 1.61 | $10.90 million | ($4.26) | -1.32 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 生物親和技術 | 不適用 | 不適用 | 不適用 | 不適用 | 不適用 |
| 通知 | 8961萬美元 | 1.61 | 1090萬美元 | ($4.26) | -1.32 |
Inotiv has higher revenue and earnings than bioAffinity Technologies.
伊諾諾夫的收入和收益高於生物親和技術公司。
Analyst Ratings
分析師評級
This is a breakdown of current ratings and recommmendations for bioAffinity Technologies and Inotiv, as reported by MarketBeat.com.
據MarketBeat.com報道，這是對BioAffity Technologies和Inuv的當前評級和推薦的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
| Inotiv | 0 | 1 | 2 | 0 | 2.67 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 生物親和技術 | 0 | 0 | 0 | 0 | 不適用 |
| 通知 | 0 | 1 | 2 | 0 | 2.67 |
Inotiv has a consensus price target of $35.00, suggesting a potential upside of 520.57%. Given Inotiv's higher probable upside, analysts clearly believe Inotiv is more favorable than bioAffinity Technologies.
伊諾諾夫的普遍目標價為35美元，這意味着潛在的上漲幅度為520.57%。考慮到伊諾科夫更有可能的上行空間，分析師們顯然認為伊諾伊諾夫比BioAffity Technologies更有利。
Summary
摘要
Inotiv beats bioAffinity Technologies on 5 of the 8 factors compared between the two stocks.
在兩隻股票之間進行比較的8個因素中，有5個因素伊諾諾夫擊敗了生物親和技術公司。
About bioAffinity Technologies
關於生物親和技術
(Get Rating)
(獲取評級)
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
生物親和技術公司是一家生物技術公司，致力於開發非侵入性診斷測試和靶向癌症療法。該公司提供CyPath肺部診斷測試，用於早期發現肺癌。它還研究在細胞水平上治療癌症的靶向療法。該公司成立於2014年，總部設在德克薩斯州聖安東尼奧。
About Inotiv
關於INotiv
(Get Rating)
(獲取評級)
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
伊諾諾夫公司為製藥、化學和醫療器械行業提供藥物發現和開發服務，並向藥物開發和合同研究行業銷售分析儀器。它通過合同研究服務和研究產品兩個部分進行運作。合同研究服務部門提供篩查和藥理測試、非臨牀安全性測試、配方開發、法規遵從性和質量控制測試服務。該部門提供分析方法開發和驗證；藥物代謝、生物分析和藥代動力學測試，以確定和測量複雜生物基質中的藥物和代謝物濃度；活體採樣服務，用於持續監測生命中的化學變化；穩定性測試，以確保非臨牀和臨牀研究中使用的各種解決方案的完整性，以及研究後分析；非臨牀毒理學和病理學服務；以及為客户的數據和樣本提供氣候控制歸檔服務。研究產品部門設計、開發、製造和銷售活體採樣系統和附件，包括一次性、培訓和系統資格；生理監測工具；液相色譜和電化學儀器平臺；包括液相和電化學儀器及其相關附件的分析產品；以及由culex系列自動活體採樣和給藥儀器組成的活體採樣產品。該公司在美國、北美其他地區、環太平洋地區、歐洲和國際上開展業務。它已與BioVaxys達成協議，為其Covid-T免疫診斷計劃進行臨牀前毒性研究。該公司前身為BioAnalytic Systems，Inc.，並於2021年3月更名為INotiv，Inc.。通知, 公司成立於1974年，總部設在印第安納州的西拉斐特。
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《生物親和技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對BioAffity Technologies及相關公司的評級的每日摘要。
譯文內容由第三人軟體翻譯。